| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2002-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22f138ff71e5dd60e9233cbfb261a924
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37e3c2d46be47c44babcac1f99511892
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb7596c6ee01ea031da8e9843322bc4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9515f979b1e99fa25c365efce232cf59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5be64d1d56feaa238feb23bd52cb6c9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98434a40921710377813e7f5d444eb10 |
| publicationDate |
2004-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2004146485-A1 |
| titleOfInvention |
Vaccines including as an adjuvant type 1 ifn and process related thereto |
| abstract |
The present invetion relates to the use of type I IFN for the preparatoin of a non toxic adjuvant compostion for enhancing TH-1 type humoral immune response to a vaccine in a in vivo protective immunization treatment weherein IFN is used in a dosage greater or equal to 100.000 U/ml, per dose of vaccine. The present invetion further relates to a kit of parts including a non-toxic adjuvant composition comprising tpye I IFN and a vaccine including at least an antigen for separate, simultaneous or sequential use in the prevention or treatment of a disease associated with the presence of said antigen. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004223949-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007249553-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022251406-A1 |
| priorityDate |
2001-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |